CSIMarket
 
Roivant Sciences Ltd   (ROIV)
 

The company declared rather influential deterioration in their top-line, amid the fiscal second quarter of 2022

company delivered second quarter of 2022 operating deficit of $-280.766 millions


Published Nov 16 2022
CSIMarket Team / CSIMarket.com


Dryvax_pdFor the fiscal span ending September 30 2022 company Losses have expanded of $-0.42 per share compare to $-0.32 a year prior and earnings per share improved from $-0.48 per share from the preceding reporting period.

Revenues decreased extensively by -10.395 % to $12.53 millions from $13.99 millions in the similar reporting period a year prior and sequentially Revenue doubled by 190.183 % from $4.32 millions.




For the fiscal span ending September 30 2022 Roivant Sciences Ltd realized net loss of $-315.921 million, bigger than $-225.640 million a year ago.


Roivant Sciences Ltd is expected to report next financial earnings on June 27, 2023.



Roivant Sciences Ltd's Executive Officers

Roivant Sciences Ltd's Free Cash Flow Margin



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com